Drugs / RO6870810

Trials 5 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03292172 Nov 2017 → Feb 2019 ovarian cancer, triple-negative breast carcinoma Hoffmann-La Roche Terminated No outcome recorded
Phase 1 NCT03255096 Aug 2017 → Jul 2019 high grade B-cell lymphoma Hoffmann-La Roche Completed No outcome recorded
Phase 1 NCT03068351 Jun 2017 → Aug 2019 plasma cell myeloma Hoffmann-La Roche Completed No outcome recorded
Phase 1 NCT02308761 Nov 2014 → Aug 2017 acute myeloid leukemia, myelodysplastic syndrome Hoffmann-La Roche Completed No outcome recorded
Phase 1 NCT01987362 Oct 2013 → Oct 2017 Hoffmann-La Roche Completed No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as RO6870810 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03292172
4

NCT03255096

NCT03068351

NCT01987362

NCT02308761

Known as (S)-JQ35 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297423
Known as Bet inhibitor ro6870810 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297423
Known as BET INHIBITOR TEN-010 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297423
Known as Jq-35, (s)- ChEMBL registry synonym — accepted as the source's own label CHEMBL4297423
Known as Rg 6146 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297423
Known as TEN-010 “RO6870810 (formerly TEN-010) is a small molecule, bromodomain and extra-terminal (BET) bromodomain inhibitor.” NCT02308761
Action Inhibit “RO6870810 is a novel, small-molecule BET inhibitor.” PMID 33311588 Dec 2020
Modality Small molecule “RO6870810 is a novel, small-molecule BET inhibitor.” PMID 33311588 Dec 2020
Route Subcutaneous “RO6870810 will be administered by subcutaneous (SC) injection” NCT01987362